Please use this identifier to cite or link to this item:
Title: Safety and Efficacy of the Newer Biological Therapeutics in the Treatment of Rheumatoid Arthritis
Authors: Navarro-Compán, Victoria
Navarro-Sarabia, Federico
metadata.dc.contributor.authoraffiliation: [Navarro-Compán,V;Navarro-Sarabia,F] Investigation Unit of Rheumatology, University Hospital Virgen Macarena, Sevilla, Spain. Department of Rheumatology,University Hospital Virgen Macarena, Sevilla, Spain.
Keywords: New targets;Monoclonal antibodies;Small molecules;Rheumatoid arthritis;Efficacy;Safety;Nuevos objetivos;Anticuerpos monoclonales;Moléculas pequeñas;Artritis reumatoide;Eficacia;Seguridad
metadata.dc.subject.mesh: Medical Subject Headings::Diseases::Musculoskeletal Diseases::Rheumatic Diseases::Arthritis, Rheumatoid
Medical Subject Headings::Chemicals and Drugs::Biological Factors::Intercellular Signaling Peptides and Proteins::Cytokines
Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Complementary Therapies
Issue Date: 15-Jul-2011
Publisher: Libertas Academica
Citation: Navarro-Compán V, Navarro-Sarabia F. Safety and Efficacy of the Newer Biological Therapeutics in the Treatment of Rheumatoid Arthritis. Clinical Medicine Insights: Therapeutics 2011 3 (195-203)
Abstract: Biological therapies have been a major advance in RA treatment. However, remission or response is not achieved in all patients. Therefore, new drugs seem necessary. Most recent trials have focused in the development of three different groups of molecules: those against commercialized targets but minimizing side effects or improving administration, others molecules against new targets, and a third group including small molecules. Some of them have been shown to be clinically efficacious and safe in RA patients, including: two new anti-TNF􀁁 therapies (golimumab and certolizumab pegol), three anti-CD (ocrelizumab, ofatumumab and a SMIP), subcutaneous abatacept, anti-IL17 therapy, tasocitinib and fostamatinib disodium. Therefore, a wide spectrum of new RA therapeutics are promising, but more studies are necessary to confirm these results.
metadata.dc.identifier.doi: 10.4137/CMT.S3781
ISSN: 1179-559X
Appears in Collections:01- Artículos - Hospital Virgen Macarena

Files in This Item:
File Description SizeFormat 
NavarroC_SatefyAndEfficacy.pdf114,2 kBAdobe PDFView/Open

This item is protected by original copyright

This item is licensed under a Creative Commons License Creative Commons